Abstract A001: Navigating the future of therapeutic development: innovations in safety and efficacy through advanced research methodologies and nanotechnology
Notice bibliographique
Résumé
Abstract In recent years, the field of therapeutic development has experienced a significant paradigm shift driven by strategic scientific innovations that prioritize safety and efficacy in therapeutic agents. This paper explores the intersection of advanced research methodologies, novel material sciences, and biotechnological advancements that are revolutionizing the approach to drug formulation and delivery systems. The integration of precision medicine principles alongside cutting-edge technologies allows for the design of therapeutics that are not only effective in targeting specific diseases but are also engineered to minimize adverse effects associated with conventional therapies. One focal point of this exploration is the application of nanotechnology in drug delivery systems. By utilizing nanoparticles, researchers can enhance the bioavailability of therapeutic agents while reducing systemic toxicity. This targeted approach enables the delivery of higher concentrations of drugs to the affected areas, thereby maximizing therapeutic efficacy and minimizing side effects. Additionally, the paper highlights the role of computational modeling and simulations in predicting the interaction of therapeutic agents at the molecular level, facilitating the identification of safer compounds through virtual screening methods. Another significant aspect addressed in this paper is the development of biologics and biosimilars as safer alternatives to traditional synthetic drugs. The advancement of biomanufacturing processes has made it feasible to produce complex molecules with high specificity and reduced immunogenicity, paving the way for innovative therapies that cater to individual patient profiles. Furthermore, the strategic incorporation of pharmacogenomics in drug development allows for the customization of therapeutic agents, ensuring that treatment regimens are tailored to the genetic makeup of patients, which can drastically improve safety and treatment outcomes. The paper also discusses the regulatory landscape surrounding the introduction of these innovative therapeutic agents. It emphasizes the need for adaptive regulatory frameworks that keep pace with scientific advancements while ensuring patient safety and efficacy. Collaborative efforts between researchers, regulatory bodies, and pharmaceutical companies are essential to facilitate the translation of innovative therapies from the laboratory to clinical practice. In conclusion, this paper underscores the critical importance of strategic scientific innovations in the quest for safer therapeutic agents. By harnessing the potential of advanced technologies, researchers can develop therapeutics that not only meet the growing demand for efficacy but also uphold the highest standards of safety, ultimately improving patient care and health outcomes. The findings presented advocate for continued investment in research and collaboration across disciplines to drive future advancements in therapeutic development. Citation Format: Peter O. David. Navigating the future of therapeutic development: innovations in safety and efficacy through advanced research methodologies and nanotechnology. [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry; 2024 Dec 9-11; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(12_Suppl):Abstract nr A001
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».